Abstract: The present invention relates to a wet wipe concentrate composition which may be blended with water or another solvent to form an impregnating formulation for a wet wipe. The present invention also relates to said wet wipe impregnating formulation and a wet wipe containing said formulation.

Abstract: The present invention provides an oral care composition comprising 4-(aminomethyl)benzoic acid in an amount of from 0.05 weight % to 5 weight %, based on the total weight of the composition.

Abstract: The present invention provides a method for removing a tattoo in a region of skin the method comprises administering to a least a portion of the tattoo, and a composition comprising an effective amount of a bisphosphonate and at least one pharmaceutically acceptable excipient to at least cause fading of the tattoo in said region.

Abstract: The invention relates to a polyribonucleotide, a cosmetic and pharmaceutical compound that has the polyribonucleotide and a medicinal product that has the polyribonucleotide and the compound.

Abstract: A thickened composition that does not lose viscosity even in the presence of an organic acid. A thickened composition, including a polyhydric alcohol, water, an organic acid, and a lipid peptide-type compound containing at least one of a compound of Formula (1) to Formula (3) below and a pharmaceutically usable salt of compound of Formula (1) to Formula (3), where R1 is a C9-23 aliphatic group, R2 is a hydrogen atom or a C1-4 alkyl group that optionally has a C1-2 branched chain, R3 is a —(CH2)n—X group, n is a number of 1 to 4, X is an amino group, guanidino group, —CONH2 group, a 5-membered ring group optionally containing 1 to 3 nitrogen atom(s), a 6-membered ring group optionally containing 1 to 3 nitrogen atom(s), or a condensed heterocycle group that contains a 5-membered ring and a 6-membered ring optionally containing 1 to 3 nitrogen atom(s).

Abstract: Water based composition comprising a sugar based delivery system, coemulsifiers and a positively charged molecule, oil, optional auxiliary materials and optional lipophilic active ingredients encapsulated to be used in Personal Care products including Cosmetics. The composition is penetrating into the skin and is, depending on the active included, able to stabilize the substance and reduce its irritation potential.

Abstract: The invention relates to a hairstyling process comprising the following steps: the application to the hair of a first cleansing cosmetic composition comprising one or more surfactants; the application of a second aqueous cosmetic composition comprising a neutralized non-crosslinked vinylpyridine polymer; followed by a step of rinsing with water and then a step of shaping the hair, and then a step of drying the hair. The invention also relates to a kit comprising a first cleansing cosmetic composition comprising one or more surfactants and a second aqueous cosmetic composition comprising a neutralized non-crosslinked vinylpyridine polymer, the first and second compositions each being packaged in a separate packaging assembly.

Abstract: A skin cleansing composition is provided. The skin cleansing composition comprises from about 0.1% to about 15%, by weight, of a plurality of biodegradable abrasive particles. The biodegradable abrasive particles comprise a safe and effective amount of polyhydroxy alkanoate (PHA) biodegradable polymeric material and comprise a particle size range from 10 ?m to 1500 ?m. The composition also comprises a multimodal particle size distribution of the biodegradable abrasive particles. The composition further comprises a dermatologically acceptable carrier.

Abstract: The invention is directed to a cosmetic which comprises an ionic silicone as described herein.

Abstract: A composition for applying to skin in need of treatment for skin barrier restoration, hydration and moisturization, the composition comprising extracts of Ampelopsis grossedentata and Albizia julibrissin. Also provided are methods for treating skin in need of skin barrier treatment, methods of treating skin to reduce the signs of aging and methods of treating skin to reduce the signs of inflammation with a composition comprising extracts of Ampelopsis grossedentata and Albizia julibrissin.

Abstract: A composition for applying to skin in need of treatment for skin barrier restoration, hydration and moisturization, the composition comprising extracts of Ampelopsis grossedentata and Albizia julibrissin. Also provided are methods for treating skin in need of skin barrier treatment, methods of treating skin to reduce the signs of aging and methods of treating skin to reduce the signs of inflammation with a composition comprising extracts of Ampelopsis grossedentata and Albizia julibrissin.

Abstract: A composition for applying to skin in need of treatment for skin barrier restoration, hydration and moisturization, the composition comprising extracts of Ampelopsis grossedentata and Albizia julibrissin. Also provided are methods for treating skin in need of skin barrier treatment, methods of treating skin to reduce the signs of aging and methods of treating skin to reduce the signs of inflammation with a composition comprising extracts of Ampelopsis grossedentata and Albizia julibrissin.

Abstract: The present invention relates to compositions and methods for the prevention and treatment of skin disorders and for the rejuvenation of the skin. In particular, the application describes topical compositions and methods of treatments comprising the combined use of one or more cannabinoids and one or more hydroxy acids in a suitable carrier.

Abstract: Inventive embodiments disclosed herein includes a cosmetic formulation. The formulation includes an extract that includes a barley grass exposed to light, the extract having a molecular oxygen partial pressure of at least about 180 mbar and a chlorophyll concentration of about 180 mg/kg.

Abstract: Disclosed is a method for preparing broccoli with increased sulforaphane content using high-voltage pulsed electric field treatment. According to the method, broccoli with increased sulforaphane content can be eaten raw or can be chopped to appropriate sizes before eating without the need to crush the broccoli. In addition, sulforaphane can be extracted from the broccoli with increased sulforaphane content. The broccoli with increased sulforaphane content and the sulforaphane extract produced therefrom can be used as an active ingredient of a food, feed or cosmetic composition to exhibit the activities of sulforaphane, including antioxidative and anti-inflammatory activities.

Abstract: Compositions for reducing skin aging are disclosed herein. The compositions can be topically applied to a skin region to reduce or prevent skin wrinkles, fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness.

Abstract: Provided is a functional cosmetic composition of white rose extract and a gartanin derivative compound isolated therefrom, and specifically, to a cosmetic composition for skin whitening and skin wrinkle alleviation containing, as active ingredients, white rose petal extract and gartanin derivative compounds isolated therefrom. The white rose extract and gartanin derivative compound, according to the present invention, are safe without causing side effects on the skin, prevent melanin production through a mechanism inhibiting tyrosinase activity, thereby having a whitening effect, and exhibit a wrinkle alleviation effect by a mechanism inhibiting MMP-1 activity, and thus the composition, of the present invention, containing the same as active ingredients, can be utilized as a material for functional cosmetics for skin whitening and wrinkle alleviation without causing skin irritation.

Abstract: Compositions for reducing skin aging are disclosed herein. The compositions can be topically applied to a skin region to reduce or prevent skin wrinkles, fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness.

Abstract: Compositions for reducing skin aging are disclosed herein. The compositions can be topically applied to a skin region to reduce or prevent skin wrinkles, fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness.

Abstract: Compositions for reducing skin aging are disclosed herein. The compositions can be topically applied to a skin region to reduce or prevent skin wrinkles, fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness.

Abstract: Compositions for reducing skin aging resulting from oxidative stress and/or photodamage are disclosed herein. The compositions can be topically applied to a skin region to reduce or prevent skin wrinkles, fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness.

Abstract: Compositions for reducing skin aging are disclosed herein. The compositions can be topically applied to a skin region to reduce or prevent skin wrinkles, fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness.

Abstract: The invention provides a skin cream comprising: about 0.5 to 15% of colostrum; about 0.5 to 15% of a polyacrylamide based emulsifier; about 1.0 to 20% of an emulsifier containing lecithin or a derivative thereof; about 1.0 to 20% of olive oil, having an acidity ranging from about 0.2 to 2.0% and a usage range of 5.0% to 50% about 1.0 to 10% of dimethicone; about 0.01% to 4.0% of alpha-tocopherol or an active derivative thereof; about 0.01% to 0.5% of vitamin A or an active vitamin A derivative; about 0.5 to 4.0% of a natural preservative; and about 10 to 90% of purified water to make up 100 percent. Application of the skin cream of the present invention should smoothly lubricate and moisturize the user's skin, and lessen the appearance of wrinkles. The skin cream of the present invention will make the skin appear smoother and more vibrant.

Abstract: Methods of protecting skin from damage due to cold thermal stress are disclosed. The methods include topically applying a composition that includes an Artemia salina extract from rehydrated Artemia salina cysts to skin at risk of damage from thermal stress, particularly from cold thermal stress or repeated temperature variations. The composition includes a physiologically acceptable medium for delivery of the Artemia salina extract.

Abstract: The invention is directed to methods of treating dermatological conditions, including cosmetic treatments intended to moisturize the epidermis, improve the firmness of the dermis, combat ageing of the skin. The methods include application of cosmetic or dermatological compositions containing mannoproteins as an active ingredient and/or adjuvant, to the use of said cosmetic or dermatological compositions and to cosmetic treatment methods.

Abstract: This invention provides the use of a polymer comprising a hyperbranched polyether polyol such as hyperbranched polyglycerol as a serum albumin substitute. Also provided are high molecular weight hyperbranched polyglycerol polymers suitable for a variety of medical and non-medical uses including methods for making such high molecular weight polymers.

Abstract: Methods and compositions for obscuring medicines formed as tablets, capsules, pills, and so forth may be presented in clean packaging, with built-in work space on a substrate, film layer. A flexible paste, gum, putty, or malleable and formable treat material may be folded without touching the actual treat composition on its outermost surface. A medicament set onto a location on a surface of the composition may then be folded inside by folding, molding, or otherwise manipulating the composition, thus forming a sealed morsel, leaving no residue (e.g., powder, scent, taste, etc.) of the medicament on the outer surface of the composition when administered to a pet.

Abstract: An orally disintegrating dosage form of a proton pump inhibitor, methods for its production and use thereof are provided.

Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

Abstract: Provided is an emulsion composition that allows a lipophilic ingredient to have high stability and high in vivo absorbability. The emulsion composition includes (a) a lipophilic ingredient, (b) a phospholipid, (c) a polyol, (d) water, (e) a sucrose fatty acid ester, and (f) a polyglycerol fatty acid ester. The content of the phospholipid (b) is from 2.0 to 15.0 parts by weight to 100 parts by weight of the total of the emulsion composition, and the weight ratio of the (f) polyglycerol fatty acid ester to the (e) sucrose fatty acid ester is from 0.1 to 0.9 parts by weight of the (f) polyglycerol fatty acid ester to 1 part by weight of the (e) sucrose fatty acid ester.

Abstract: A stable liposomal formulation for ocular delivery of a carbonic anhydrase inhibitor. The formulation contains (i) a liposome that includes a lipid bilayer formed of a phosphatidylcholine, and (ii) a carbonic anhydrase inhibitor encapsulated in the liposome. Also provided is a method for treating an ocular disorder with the formulation.

Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a drug in a dissolved state, an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase, and a release rate of the drug from each of the liposomes is 10%/24 hr to 70%/24 hr in blood plasma at 37° C.; and a method for producing the same.

Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.

Abstract: Provided is a method for producing a liposome having safety and stability. According to the present invention, it is possible to provide a method for producing a liposome, including a step of mixing an oil phase with at least one lipid dissolved in an organic solvent and a water phase and stirring an aqueous solution containing the lipids, and a step of evaporating the organic solvent from the aqueous solution containing the liposomes obtained in the stirring step, in which the organic solvent is a mixed solvent of a water-soluble organic solvent and an ester-based organic solvent.

Abstract: Provided are a liposome composition in which an osmotic pressure of an inner water phase is 2-fold to 8-fold relative to the osmotic pressure of an outer water phase, and which encapsulates a water-soluble drug in a dissolved state, and also exhibits excellent preservation stability; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes obtained from lipids dissolved and emulsified in an organic solvent, each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a water-soluble drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase; and a method for producing the same.

Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.

Abstract: In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection.

Abstract: Formulations and methods are disclosed which provide controlled, sustained release of a biologic therapeutic to a space within the body. More specifically, formulations comprising a plurality of hydrophilic polymer strands, and methods of forming and administering such formulations, are disclosed. In some embodiments, the formulations exhibit a burst release, an initial release, a triphasic release, and release over thirty to ninety days of the biologic therapeutic. In some embodiments, the formulations exhibit reversible precipitation of the biologic therapeutic into precipitates having a diameter of about 50 nm to about 10 ?m.

Abstract: A method is provided for preparing spray dried powder containing vancomycin hydrochloride. The method comprises providing a vancomycin hydrochloride solution with a chromatographic purity of at least 95%, adding an excipient to the vancomycin hydrochloride solution to form a mixture solution of the vancomycin hydrochloride solution and the excipient, concentrating the mixed solution of the vancomycin hydrochloride solution and the excipient to form a 20% to 30% vancomycin concentrate, filtering the vancomycin concentrate to form a final filtrate, and spray drying the final filtrate to form a spray dried vancomycin hydrochloride powder with EP impurity B level of not more than 1.5%.

Abstract: The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.

Abstract: The present disclosure provides targeted, polymeric nanoparticles which facilitate the delivery of small interfering RNAs, miRNAs and shRNA expressing plasmid DNAs and include an aggregate of nucleic acids and polycationic polymer scaffolds. Methods of making and using such nanoparticles are provided as are methods of treating cancer, including Glioblastoma Multiforme, prostate cancer and melanoma using such nanoparticles.

Abstract: An alginate and stearic acid composition is described, including methods of molding it into tablets further comprising a drug, and methods of controlling the drug release from the tablets.

Abstract: A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component.

Abstract: A process of producing a non-sticky nanofibrous membrane includes pouring dimethylformamide (DMF) and dichloromethane into a first flask; pouring about 1 to about 40 wt % of polycaprolactone (PCL) into the first flask to prepare a PCL solution therein; keeping the first flask in a predetermined temperature wherein volumetric ratio of DMF and dichloromethane is 1:9 to 9:1; pouring hyaluronic acid (HA) into a second flask to prepare an HA solution having 1.75 wt % of HA; and activating an electrospinning technique to process the PCL solution in the first flask and the HA solution in the second flask, thereby producing an NFM having a core and a shell.

Abstract: Microbial infections have become increasingly difficult to treat due to the emergence of drug resistant microbes. Adjunctive therapies can be used to better treat resistant microbes, where multiple drugs are concurrently used to overcome resistant mechanisms and to synergistically treat infections. The practice of adjunctive therapies is limited by the ability to precisely control the pharmacokinetic profiles of the multiple actives. Composite particle-based approaches to enable and enhance adjunctive antimicrobial infections by simultaneous encapsulation and delivery of all components are described herein.

Abstract: Embodiments disclosed herein relates to ganglioside GM3-containing mixed lipids nanoparticles having an overall size between 60-100 nm, the making thereof and the uses. The nanoparticles selectively targeted to CD169+ expressing cells such as dendritic cells and macrophage. The nano-particles are endocytosed by the CD169+ expressing cells.

Abstract: The present invention provides a lipid nano-particles, which allow nucleic acids to be easily introduced into cells, comprising a cationic lipid represented by formula (I) (wherein: R1 and R2 are, the same or different, alkenyl, etc, and X3 is absent or is alkyl, etc, X1 and X2 are hydrogen atoms, or are combined together to form a single bond or alkylene, and Y1 is absent or anion, L1 is a single bond, etc, R3 is alkyl, etc), and the like.

Abstract: Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.

Abstract: Proteinoid compounds characterized by a molecular weight (Mw) of at least 15,000 Da, processes of preparing such compounds and methods of use thereof, are provided. A method of monitoring the presence and metastases of cancer in a body of an individual is further disclosed.

Abstract: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.